• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

雷珠单抗和贝伐单抗而非阿柏西普在体外抑制原代人视网膜色素上皮细胞的增殖。

Ranibizumab and Bevacizumab but Not Aflibercept Inhibit Proliferation of Primary Human Retinal Pigment Epithelium in vitro.

作者信息

Parisi Lorenzo, Fuhrer Reto, Zinkernagel Martin, Enzmann Volker

机构信息

Department of Ophthalmology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Department of Biomedical Research, University of Bern, Bern, Switzerland.

出版信息

Ophthalmologica. 2019;241(3):137-142. doi: 10.1159/000490430. Epub 2018 Jul 12.

DOI:10.1159/000490430
PMID:30001546
Abstract

AIM

Treatment of exudative age-related macular degeneration by using vascular endothelial growth factor (VEGF) antagonists is the gold standard today. So far, several bioactive molecules have been approved for therapeutic use. In this study, we investigate the effects of ranibizumab (Lucentis®), bevacizumab (Avastin®), and aflibercept (Eylea®) on primary human retinal pigment epithelial (hRPE) cells in vitro.

METHODS

hRPE cells were prepared from donor eyes and cultured under standard culture conditions. Scleral fibroblasts also prepared from donor tissue served as physiological controls. The impact of the anti-VEGF molecules on cell viability was investigated with the trypan blue exclusion assay, whereas proliferation was measured using the MTT assay. Biological activity of the molecules was quantified in a VEGF-enzyme-linked immunosorbent assay (ELISA).

RESULTS

All tested substances were biologically active in vitro. They displayed no cytotoxicity on RPE cells or scleral fibroblasts. However, proliferation of RPE cells was significantly decreased after treatment with ranibizumab or bevacizumab but not with aflibercept.

CONCLUSIONS

The humanized antibodies (fragments) interfered specifically with the RPE cells. The thereby measured inhibition of cell proliferation may indicate possible side effects on the physiology of RPE cells.

摘要

目的

使用血管内皮生长因子(VEGF)拮抗剂治疗渗出性年龄相关性黄斑变性是目前的金标准。到目前为止,已有几种生物活性分子被批准用于治疗。在本研究中,我们在体外研究了雷珠单抗(Lucentis®)、贝伐单抗(Avastin®)和阿柏西普(Eylea®)对原代人视网膜色素上皮(hRPE)细胞的影响。

方法

从供体眼中制备hRPE细胞,并在标准培养条件下培养。同样从供体组织制备的巩膜成纤维细胞作为生理对照。用台盼蓝排斥试验研究抗VEGF分子对细胞活力的影响,而用MTT试验测量细胞增殖。在VEGF酶联免疫吸附测定(ELISA)中对分子的生物活性进行定量。

结果

所有测试物质在体外均具有生物活性。它们对RPE细胞或巩膜成纤维细胞均无细胞毒性。然而,用雷珠单抗或贝伐单抗治疗后,RPE细胞的增殖显著降低,但用阿柏西普治疗后则没有。

结论

人源化抗体(片段)特异性干扰RPE细胞。由此测得的细胞增殖抑制可能表明对RPE细胞生理有潜在副作用。

相似文献

1
Ranibizumab and Bevacizumab but Not Aflibercept Inhibit Proliferation of Primary Human Retinal Pigment Epithelium in vitro.雷珠单抗和贝伐单抗而非阿柏西普在体外抑制原代人视网膜色素上皮细胞的增殖。
Ophthalmologica. 2019;241(3):137-142. doi: 10.1159/000490430. Epub 2018 Jul 12.
2
Long-term treatment with anti-VEGF does not induce cell aging in primary retinal pigment epithelium.抗血管内皮生长因子的长期治疗不会诱导原代视网膜色素上皮细胞衰老。
Exp Eye Res. 2018 Jun;171:1-11. doi: 10.1016/j.exer.2018.03.002. Epub 2018 Mar 6.
3
Effects of Ranibizumab, Bevacizumab, and Aflibercept on Senescent Retinal Pigment Epithelial Cells.雷珠单抗、贝伐单抗和阿柏西普对衰老视网膜色素上皮细胞的影响。
Korean J Ophthalmol. 2018 Aug;32(4):328-338. doi: 10.3341/kjo.2017.0079.
4
Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture.抗血管内皮生长因子药物的安全性:贝伐单抗、雷珠单抗、阿柏西普和泽必泰在培养的人视网膜色素上皮细胞中的安全性。
Br J Ophthalmol. 2014 Jun;98 Suppl 1(Suppl 1):i11-16. doi: 10.1136/bjophthalmol-2014-305302.
5
Response to anti-VEGF-A treatment of retinal pigment epithelial cells in vitro.体外视网膜色素上皮细胞对抗VEGF-A治疗的反应。
Eur J Ophthalmol. 2016 Aug 4;26(5):425-30. doi: 10.5301/ejo.5000786. Epub 2016 Apr 12.
6
Effects of bevacizumab, ranibizumab, and aflibercept on phagocytic properties in human RPE cybrids with AMD versus normal mitochondria.贝伐单抗、雷珠单抗和阿柏西普对 AMD 与正常线粒体人 RPE 细胞融合体吞噬特性的影响。
Exp Eye Res. 2018 Dec;177:112-116. doi: 10.1016/j.exer.2018.07.025. Epub 2018 Jul 30.
7
Comparison of the efficacy of aflibercept, ranibizumab, and bevacizumab in an RPE/choroid organ culture.阿柏西普、雷珠单抗和贝伐单抗在视网膜色素上皮/脉络膜器官培养中的疗效比较。
Graefes Arch Clin Exp Ophthalmol. 2014 Oct;252(10):1593-8. doi: 10.1007/s00417-014-2719-y. Epub 2014 Jul 22.
8
Differential effects of bevacizumab, ranibizumab and aflibercept on cell viability, phagocytosis and mitochondrial bioenergetics of retinal pigment epithelial cell.贝伐单抗、雷珠单抗和阿柏西普对视网膜色素上皮细胞活力、吞噬作用及线粒体生物能量学的不同影响
Acta Ophthalmol. 2015 Dec;93(8):e631-43. doi: 10.1111/aos.12745. Epub 2015 May 14.
9
PERMEABILITY AND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR EFFECTS OF BEVACIZUMAB, RANIBIZUMAB, AND AFLIBERCEPT IN POLARIZED RETINAL PIGMENT EPITHELIAL LAYER IN VITRO.贝伐单抗、雷珠单抗和阿柏西普在体外极化视网膜色素上皮层中的通透性及抗血管内皮生长因子作用
Retina. 2017 Jan;37(1):179-190. doi: 10.1097/IAE.0000000000001117.
10
Effects of VEGF inhibitors on human retinal pigment epithelium under high glucose and hypoxia.血管内皮生长因子抑制剂对高糖缺氧下人视网膜色素上皮的作用。
Clin Exp Ophthalmol. 2019 Nov;47(8):1074-1081. doi: 10.1111/ceo.13579. Epub 2019 Jul 22.

引用本文的文献

1
In vitro and in ovo experimental study of two anti-VEGF agents used in ophthalmology.眼科中两种抗 VEGF 药物的体外和鸡胚实验研究。
Rom J Morphol Embryol. 2021 Jul-Sep;62(3):801-806. doi: 10.47162/RJME.62.3.18.
2
Properdin Modulates Complement Component Production in Stressed Human Primary Retinal Pigment Epithelium Cells.备解素调节应激状态下人类原代视网膜色素上皮细胞中的补体成分生成。
Antioxidants (Basel). 2020 Aug 26;9(9):793. doi: 10.3390/antiox9090793.
3
Co-inhibition of PGF and VEGF blocks their expression in mononuclear phagocytes and limits neovascularization and leakage in the murine retina.
PGF 和 VEGF 的共抑制作用阻断了单核吞噬细胞中它们的表达,并限制了小鼠视网膜中的新生血管形成和渗漏。
J Neuroinflammation. 2019 Feb 7;16(1):26. doi: 10.1186/s12974-019-1419-2.